Mammary Cell News Volume 12.05 | Feb 13 2020

TOP STORY

C/EBPɑ Is Crucial Determinant of Epithelial Maintenance by Preventing Epithelial-to-Mesenchymal Transition

Scientists identified C/EBPα as one of the most TGF-β-mediated downregulated transcription factors in human mammary epithelial cells. C/EBPα expression prevented TGF-β-driven epithelial-to-mesenchymal transition (EMT) by inhibiting expression of known EMT factors. [Nat Commun] Full Article

(Ranked by impact factor of the journal)

Autophagy Regulates Functional Differentiation of Mammary Epithelial Cells

Using lactogenic differentiation of the HC11 mouse mammary epithelial cell line, researchers demonstrated that HC11 cells transitioned to a highly energetic state during differentiation by engaging both oxidative phosphorylation and glycolysis. [Autophagy] Abstract

A Role for CBFβ in Maintaining the Metastatic Phenotype of Breast Cancer Cells

Investigators demonstrated that CBFβ was essential to maintain the mesenchymal phenotype of triple-negative breast cancer cells and that CBFβ-depleted cells underwent a mesenchymal to epithelial transition and re-organized into acini-like structures. [Oncogene] Full Article

G Protein-Coupled Kisspeptin Receptor Induces Metabolic Reprogramming and Tumorigenesis in Estrogen Receptor-Negative Breast Cancer

The G protein-coupled kisspeptin receptor was highly expressed in patient triple-negative breast cancer tumors and promoted malignant transformation of breast epithelial cells. [Cell Death Dis] Full Article

Screening of Potential miRNA Therapeutics for the Prevention of Multi-Drug Resistance in Cancer Cells

To investigate the enhancement of chemotherapeutics in cancer cells, high MGMT expressing glioblastoma and a high ABCB1 expressing triple-negative breast cancer cell line were treated with varying concentrations of chemotherapeutics and corresponding miRNAs. [Sci Rep] Full Article

SETD3 Acts as a Prognostic Marker in Breast Cancer Patients and Modulates the Viability and Invasion of Breast Cancer Cells

In vitro assays were performed to assess the role of SET Domain Containing 3, Actin Histidine Methyltransferase (SETD3) in the viability and capacity of invasion of human breast cancer cell lines. [Sci Rep] Full Article

Long Non-Coding RNA TUSC8 Inhibits Breast Cancer Growth and Metastasis via miR-190b-5p/MYLIP Axis

Knock-down of tumor suppressor candidate 8 (TUSC8) drastically promoted the proliferation, migration and invasion of breast cancer cells in vitro and facilitated tumorigenicity and metastasis in vivo. [Aging (Albany NY)] Full Article

Estradiol-Induced MMP-9 Expression via PELP1-Mediated Membrane-Initiated Signaling in ERα-Positive Breast Cancer Cells

Investigators demonstrated that estradiol-induced estrogen receptor (ER)α-positive MCF-7 breast cancer cell MMP-9 mRNA and protein expression in a rapid response and concentration-dependent manner. [Horm Cancer] Abstract

Fangjihuangqi Decoction Inhibits MDA-MB-231 Cell Invasion In Vitro and Decreases Tumor Growth and Metastasis in Triple-Negative Breast Cancer Xenografts Tumor Zebrafish Model

Researchers showed that TGFβ1-induced MDA-MB-231 cell morphology change, promoted MDA-MB 231 invasion, increased Vimentin expression, and decreased E-cadherin expression. [Cancer Med] Full Article

1,25-Hydroxyvitamin D₃ Decreases Endoplasmic Reticulum Stress-Induced Inflammatory Response in Mammary Epithelial Cells

The effect of active vitamin D₃ hormone (1,25D₃) was studied on induction of endoplasmic reticulum stress in a transformed human mammary epithelial cell line, MCF-7 cells. [PLoS One] Full Article

Nucleosome Destabilization by Nuclear Non-Coding RNAs

Scientists detected nucleosome depletion around the transcription site of Eleanor2, the most highly expressed Eleanor in long-term estrogen deprivation cells. [Commun Biol] Abstract

Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News.

Breast Cancer Models: Engineering the Tumor Microenvironment

The authors give an overview of the breast cancer tumor microenvironment, and then discuss the current state of the pre-clinical breast cancer models, with a focus on the engineered three dimensional tissue models. [Acta Biomater] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Merck’s KEYTRUDA^® (Pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC)

Merck, Inc. announced that the pivotal Phase III KEYNOTE-355 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met one of its dual primary endpoints of progression-free survival in patients with mTNBC whose tumors expressed PD-L1. [Merck, Inc. (Business Wire, Inc.)] Press Release

Seattle Genetics Announces FDA Filing Acceptance for Priority Review of Tucatinib New Drug Application (NDA) for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer

Seattle Genetics, Inc. announced that the FDA has accepted for priority review the company’s New Drug Application for the investigational medicine tucatinib. [Seattle Genetics, Inc.] Press Release

Popular Preprint Servers Face Closure Because of Money Troubles

The rise of preprint repositories has helped scientists worldwide to share results and get feedback quickly. But several platforms that serve researchers in emerging economies are struggling to raise money to stay afloat. Repositories like INA-Rxiv and IndiaRxiv boost regional science, but finding cash to run them is proving difficult. [Nature News] Editorial

FDA Now Allows Certain Lab Animals to Be Retired and Adopted

The US Food and Drug Administration will now permit certain animals used in experiments to retire and be adopted rather than face euthanasia, according to internal documents reviewed by The Hill. Although the policy changed in November, there have not been any public statements from the agency. [The Scientist] Editorial

NEW International Society for Stem Cell Research (ISSCR) Annual Meeting
June 24-27, 2020
Boston, Massachusetts, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Research Position – Breast Cancer Research (The University of Texas)

NEW Postdoctoral Position – Breast Cancer Metastasis (University of Kentucky)

Research Fellow – Breast Cancer (Dana-Farber Cancer Institute)

Postdoctoral Researcher – Cancer Pathogenesis (National University of Ireland Galway)

Postdoctoral Fellow – Breast Tumorigenesis (University of Cincinnati)

Research Fellow – Anti-Cancer Therapy (Mayo Clinic)

Postdoctoral Position – DNA Nanotechonology in Cancer (University of Duisburg-Essen)

Postdoctoral Fellow – Clonal Evolution of Cancer (Moffitt Cancer Center & Research Institute)

Postdoctoral Fellowship – Breast Cancer Immunology and Immunotherapy (The University of Texas Southwestern)

Investigator Position – Cancer Cell Biology (Winthrop P. Rockefeller Cancer Institute)

Postdoctoral Research Fellow – Breast Cancer Research (University of South Carolina)

Postdoctoral Fellow – Brain Metastasis in Aggressive Breast Cancers (The University of Texas MD Anderson Cancer Center)

Postdoctoral Associate – Immune Responses (The Jackson Laboratory)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.